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Abstract
Aberrant activation of the Wnt pathway contributes to human cancer progression. Antagonists that interfere with Wnt
ligand/receptor interactions can be useful in cancer treatments. In this study, we evaluated the therapeutic potential of
a soluble Wnt receptor decoy in cancer gene therapy. We designed a Wnt antagonist sLRP6E1E2, and generated
a replication-incompetent adenovirus (Ad), dE1-k35/sLRP6E1E2, and a replication-competent oncolytic Ad, RdB-k35/
sLRP6E1E2, both expressing sLRP6E1E2. sLRP6E1E2 prevented Wnt-mediated stabilization of cytoplasmic b-catenin,
decreased Wnt/b-catenin signaling and cell proliferation via the mitogen-activated protein kinase, and phosphatidylinositol
3-kinase pathways. sLRP6E1E2 induced apoptosis, cytochrome c release, and increased cleavage of PARP and caspase-3.
sLRP6E1E2 suppressed growth of the human lung tumor xenograft, and reduced motility and invasion of cancer cells. In
addition, sLRP6E1E2 upregulated expression of epithelial marker genes, while sLRP6E1E2 downregulated mesenchymal
marker genes. Taken together, sLRP6E1E2, by inhibiting interaction between Wnt and its receptor, suppressed Wnt-induced
cell proliferation and epithelial-to-mesenchymal transition.
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Introduction
Lung cancer is highly aggressive and the most common cause of
cancer-related deaths worldwide. In 2009, the American Cancer
Society estimated that there were 219,440 new cases of lung
cancer in the United States. Standard therapies such as surgery
and radiation are not effective in many cases [1]; however, an
increased understanding of the molecular mechanisms of lung
cancer has led to the development of promising new therapies [2].
Although chemotherapy advances have improved overall survival
for patients with aggressive non-small cell lung cancer, chemore-
sistance remains a major cause of treatment failure [3]. Many
aggressive lung cancers show alterations in various cancer-
associated genes, including Wnt, K-ras, extracellular signal-
regulated kinase (ERK), Akt, and cyclooxygenase-2, suggesting
a different molecular pathway for carcinogenesis in lung
adenocarcinomas [4–6].
The role of Wnt signaling in cancer was first suggested 20
years ago with the discovery of Wnt-1 as an integration site for
mouse mammary tumor virus [7]. Many studies have reported
that altered expression of Wnt ligands, receptors, and extracel-
lular antagonists are associated with cancer development/pro-
gression and stem cell self-renewal/differentiation [8]. Expression
of the Wnt ligand, low-density lipoprotein receptor–related
protein 5 (LRP5), and LRP6 are upregulated in lung cancers,
whereas Wnt antagonists that bind Wnt ligands to block
interaction with receptors (e.g., Wnt inhibitory factor-1 (WIF-
1), secreted Frizzled-related proteins (sFRP) and dickkopf
proteins (DKK) are downregulated or inactivated [9,10].
Accordingly, monoclonal antibodies and small interfering RNAs
against Wnt and overexpression of Wnt antagonists suppress
tumor growth in various in vitro and in vivo tumor models.
LRP6, a member of the LRP superfamily, is required for
activation of the canonical Wnt signaling pathway, which leads to
the stabilization and nuclear translocation of b-catenin, the key
effector molecule [11]. LRP6 consists of four distinct YWTD b-
propeller/EGF-like domain pairs; the first and second YWTD
domains (E1 and E2) are required for binding to Wnt [12–14]. In
the present study, we explored the therapeutic potential of a novel
soluble Wnt receptor, sLRP6E1E2, which is composed of the
LRP6 E1 and E2 regions. We examined the biological effects of
sLRP6E1E2 binding to extracellular Wnt ligands and blocking
ligand-receptor interactions. Our results provide direct evidence
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36520Figure 1. Characterization of the decoy Wnt receptor sLRP6E1E2. (a) Schematic representation of the genomic structure of Ad vectors used.
(b) Endogenous Wnt3a (left panel) and LRP6 (right panel) expression in several human lung cancer cell lines. (c) Secretion and expression of
sLRP6E1E2. Cell culture supernatants were assessed with FLAG specific Ab (Upper panel). Ponceau staining is shown as loading control (Bottom
panel). (d) H322 and H460 cells were transduced with dE1-k35/LacZ or dE1-k35/sLRP6E1E2 (50 MOI) for 48 hr. Cell lysates were immunoprecipitated
with antisera against Wnt3a (IP: Wnt3a) or LRP6 (IP: LRP6) followed by western blot analysis with the same antibodies.
doi:10.1371/journal.pone.0036520.g001
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Materials and Methods
Ethics Statement
Animal handling was conducted in accordance with national
and international guidelines, in an animal facility accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC). The number of animals used was
minimized, and all necessary precautions were taken to mitigate
pain or suffering. Protocols were approved by the Institutional
Animal Care and Use Committee at Yonsei University health
system (2010-0160).
Materials
Polyclonal antibodies against MAPK kinase (MEK1/2), p44/42
mitogen-activated protein kinase (MAPK; Erk1/2), mTOR,
phosphatidylinositol 3-kinase (PI3K) and Akt, and monoclonal
antibodies against Wnt3a, Dvl2, Axin, glycogen synthase kinase
(GSK3-b), poly (ADP-ribose) polymerase (PARP), and cleaved
caspase-3 were purchased from Cell Signaling Technology
(Beverly, MA). Antibodies against epithelial-to-mesenchymal
transition (EMT)-related molecules b-catenin, E-cadherin and
vimentin were obtained from Cell Signaling Technology, and
antibody against N-cadherin was purchased from eBioscience (San
Diego, CA). Antibodies against cyclin D1 (H-295), cytochrome c
(C-20 for Western blot analysis), and LRP6 (C-10), and protein A/
G agarose beads were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Monoclonal antibody against caspase-3 was
from StressGen Biotechnologies (Victoria, BC). Polyclonal anti-
body against cytochrome c (6H2.B4 for Immunohistochemistry)
was from BD Pharmingen (San Diego, CA). Alexa Fluor 488-
conjugated and Alexa Fluor 568-conjugated anti-rabbit IgG
antibodies were obtained from Invitrogen (Carlsbad, CA). DAPI
(1 mg/ml), Hoechst 33342, and tetramethylrhodamine isothiocya-
nate (TRITC)-conjugated phalloidin were from Sigma (St. Louis,
MO). Purified Wnt3a protein was purchased from R&D Systems
(Minneapolis, MN).
Cell Lines and Culture Conditions
Non-small cell lung cancer cell lines A549, H460, H358, and
H596 were maintained in Dulbecco’s modified high-glucose
Eagle’s medium (DMEM; Life Technologies, Grand Island, NY);
H322, H2009 and H1299 cell lines were cultured in RPMI 1640
(Life Technologies) medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% MEM
nonessential amino acids, penicillin-streptomycin (100 IU/ml),
and Hank’s balanced salt solution (Life Technologies). Cells were
purchased from the American Type Culture Collection (Manassas,
VA) and maintained at 37uC in a humidified chamber at 5% CO2.
Generation of Adenoviral Vectors Expressing Soluble
LRP6 Receptor
To study the biochemical function of soluble LRP6 receptor
(sLRP6E1E2), we generated constructs of the E1 and E2
extracellular domains (Wnt-binding sites) of LRP6 [15] and
FLAG-tagged sLRP6E1E2 was subcloned into a pCA14 shuttle
vector [16]. This pCA14-sLRP6E1E2 vector was co-transformed
with a replication-incompetent adenovirus 5/35 chimeric vector
(dE1-k35) or replication-competent chimeric oncolytic adenovirus
vector (RdB-k35) [17], generating pdE1-k35/sLRP6E1E2 and
pRdB-k35/sLRP6E1E2, respectively. These recombinant plas-
mids were transfected into HEK293 cells to generate dE1-k35/
sLRP6E1E2 and RdB-k35/sLRP6E1E2. The replication-incom-
petent dE1-k35/LacZ and replication-competent oncolytic RdB-
k35 vectors were used as negative controls [18] (Fig. 1A). All
viruses were obtained as previously described [19].
Luciferase Reporter Assay for b-catenin Activity
TOPflash and FOPflash luciferase reporter vectors (Upstate
Biotechnology, Lake Placid, NY) were used to measure b-
catenin/T-cell factor (TCF) signaling activity. A549, H322, and
H460 cells were seeded into 6-well plates and transfected with
0.3 mg TOPflash (containing wild-type TCF binding sites) or
FOPflash (containing mutated TCF binding sites) negative
control with dE1-k35/LacZ or dE1-k35/sLRP6E1E2 (20,
50 MOI) in serum-free medium. After 12 hr, the medium was
replaced with 1% DMEM with or without 100 ng/ml of Wnt3a,
and the cells were incubated for another 24 hr. Cells were lysed
with passive lysis buffer, and 20 ml of the cell extract was
analyzed using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI). Experiments were carried out in
triplicate and repeated at least three times.
siRNA Transfection
siRNA transfection was performed as described previously
[20]. Briefly, cells were grown in six-well plate to 60% confluence
and immediately before transfection washed with serum free
medium, and 800 ml of serum-free medium were added per well.
Mixture of 0.3 mg TOPflash vector, LRP6-specific or control
siRNA (10 nM), and 5 ml of lipofectamine (Invitrogen) in 200 ml
of serum-free medium was then incubated for 20 min at room
temperature and added into each well. Serum was added 8 hr
later to a final concentration of 10%. The next day, cells were
stimulated with or without recombinant Wnt3a (100 ng/ml) for
an additional 16 hr.
Cell Proliferation Assay
The cell proliferation assay was determined by 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT)
assay (Sigma). A549 and H322 cells were seeded in 24-well plates
(2610
4 cells/well). After 24 hr, cells were treated with PBS, dE1-
k35/LacZ, or dE1-k35/sLRP6E1E2. The next day, cells were
stimulated with or without recombinant Wnt3a (100 ng/ml) for an
additional 48 hr. Absorbance at 540 nm was read on a microplate
reader. All assays were performed in triplicate.
Western Blotting
Cells cultured in DMEM with 1% fetal bovine serum in 100-
mm plates were transduced with dE1-k35/LacZ or dE1-k35/
sLRP6E1E2. The next day, cells were treated with or without
Wnt3a (100 ng/ml) for 16 hr. Immunoblotting was performed as
described previously [17]. Blocked membranes were incubated
with antibodies against Wnt3a, FLAG, LRP6, Dvl2, Axin, cyclin
D1, GSK3-b, MEK1/2, p44/42 MAPK (Erk1/2), Survivin,
mTOR, PI3K, Akt, PARP, pro-caspase 3, cleaved-caspase 3,
and cytochrome c overnight at 4uC. The blots were incubated with
the following secondary antibodies conjugated to horseradish
peroxidase: goat anti-rabbit IgG, goat anti-mouse IgG, or mouse
anti-goat IgG (Cell Signaling Technology) and developed using
enhanced chemiluminescence (Amersham Pharmacia Biotech,
Uppsala, Sweden).
Immunoprecipitation Analysis
H322 and H460 cells seeded on 10-cm dishes were infected with
each Ad (MOI, 50). Forty-eight hours postinfection, the cells were
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0.15 M NaCl, 0.5% Nonidet P-40, and proteinase inhibitors
phenylmethylsulfonyl fluoride, tosyl-l-lysine chloromethyl ketone,
and N-tosyl-l-phenylalanine chloromethyl ketone). The total cell
lysate (500 mg) was first immunoprecipitated with Wnt3a or LRP6
antibody and analyzed by Western blot with anti-Wnt3a and anti-
LRP6 antibody.
Immunofluorescence Assay
For immunofluorescence microscopy, cultured cells werewashed
twice with PBS, fixed in 4% paraformaldehyde for 10 min at room
temperature, and then permeabilized by incubation for 15 min
with 0.1% Triton X-100 in PBS. The samples were blocked with
1% bovine serum albumin followed by incubation with E-cadherin,
b-catenin, or anti-cytochrome c primary antibodies overnight at
4uC. The next day, cells were washed with PBS and incubated with
Alexa Flour 488-conjugated goat anti-rabbit IgG secondary
antibody for 60 min at room temperature. The final antibody
treatment also contained TRITC-conjugated actin and Hoechst
33342 or DAPI stain (both at 1 mg/ml, Sigma) for nuclear staining.
Slides were mounted with Vectashield mounting medium (Vector
Laboratories, Burlingame, CA), and cells were viewed under
a confocal laser-scanning microscope (LSM510, Carl Zeiss
MicroImaging, Thornwood, NY).
Mitochondrial Fractionation and Western Blotting
Mitochondrial fractions were prepared using the Qproteome
mitochondria isolation kit (QIAGEN, Hilden, Germany) follow-
ing the manufacturer’s instructions. Cells washed with 0.9%
sodium chloride solution were suspended with ice-cold lysis
buffer by pipetting up and down. After a 10-min incubation,
lysate was centrifuged at 1000 g for 10 min at 4uC, and the
supernatant containing cytosolic proteins was carefully removed.
The pellet containing nuclei, cell debris, and unbroken cells was
resuspended with ice-cold disruption buffer and centrifuged at
1000 g for 10 min at 4uC, and the supernatant (microsomal
fraction) was transferred to a clean microtube. The resulting
pellet containing mitochondria was washed with the mitochon-
dria storage buffer and centrifuged at 6000 g for 20 min at 4uC;
a band toward the bottom of the tube was harvested as
a mitochondrial fraction. Western blotting was performed with
the rabbit anti-cytochrome c antibody using the procedure
described above.
Anti-tumor Effects in Human Xenograft Model
Human non-small cell lung cancer (H460) xenograft was
established in 6- to 8-week-old male athymic nu/nu mice (Charles
River Japan, Yokohama, Japan) by subcutaneous implantation of
1610
7 H460 cells in the abdomen. When tumor volumes reached
approximately 80–100 mm
3, the mice were divided five groups
with similar mean tumor volumes. Adenoviral vectors were
administered intratumorally (2610
10 viral particles/mouse) on
the first day of treatment (day 1) and days 3 and 5. All animal
studies were conducted in the Yonsei University College of
Medicine according to institutional regulations, in an animal
facility accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC). Tumor
volume (V) was calculated as V =0.526a
26b (a, smallest superficial
diameter; b, largest superficial diameter).
Tumor Histology and Immunohistochemistry
Tumor tissue was fixed in 4% paraformaldehyde and embedded
in paraffin wax for histologic examination and immunohisto-
chemical staining. Representative sections were stained with
hematoxylin and eosin and examined by light microscopy. To
quantify capillary density and Wnt expression, the tumor sections
were stained with anti-mouse CD31 IgG (BD Pharmingen), anti-
rabbit b-catenin IgG (Cell Signaling Technology), or anti-mouse
Wnt3a IgG (Santa Cruz Biotechnology). After quenching endog-
enous peroxidase activity and blocking non-specific protein
binding with normal goat serum (Vector Laboratories), sections
were incubated with primary antibodies at 4uC overnight, and
then with biotinylated secondary IgG (Jackson ImmunoResearch,
West Grove, PA). Positive immunoreactivity was visualized with
ABC-peroxidase kits (ChemMate
TM DAKO Envision
TM De-
tection kit; DAKO). Controls were prepared by incubating with
irrelevant class-matched and species-matched IgGs. All slides were
counterstained with Mayer’s hematoxylin. The expression levels of
Wnt3a and b-catenin were assessed semi-quantitatively using
MetaMorphH image analysis software (Universal Image Corp.,
Westchester, PA). Results were expressed as mean optical density
for five different digital images.
Terminal Deoxynucleotidyl Transferase dUTP Nick End
Labeling Assay
The 5-mm formalin-fixed and paraffin-embedded tissue sections
were deparaffinized and rehydrated according to standard
protocols [21]. Apoptosis was detected with the terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay (DeadEnd
TM Fluorometric TUNEL System; Promega).
Briefly, tissue sections were permeabilized with proteinase K
(20 mg/ml) for 10 min at room temperature. Sections were then
incubated with terminal deoxynucleotidyl transferase (TdT) and
fluorescein-12-dUTP in TdT buffer at room temperature for
60 min and washed with TdT buffer. Finally, nuclei were
counterstained with DAPI. The samples were analyzed by
fluorescence microscopy using a standard fluorescent filter.
Migration and Invasion Assay
In vitro migration assays were performed as described previously
[22]. Briefly, the lower surface of 6.5-mm polycarbonate filters (8-
mm pore size; Corning Costar, Cambridge, MA) was coated by
immersion in 0.1% gelatin. Conditioned media was obtained from
A549 cells transduced with PBS, dE1-k35/LacZ and dE1-k35/
sLRP6E1E2 after treatment with or without Wnt3a and placed in
the bottom Transwell chamber. A549 cells were then plated on the
upper chamber (7610
4 cells/well). Cultures were incubated at
37uC for 4 hr, fixed, and stained with hematoxylin and eosin. In
vitro Matrigel invasion assays were performed using bio-coat cell
migration chambers. Filters (8-mm pore) were coated with Matrigel
basement membrane matrix (37 mg/filter; BD Biosciences, San
Jose, CA), and the experiment was performed as described for the
cell migration assay. After 24 hr, noninvading cells were removed,
and the invading cells on the under surface of the filter were fixed
and stained. The membranes were mounted on glass slides, and
migrated cells were counted at 2006 magnification. Five fields
were counted for each assay, and experiments were repeated at
least three times.
Statistical Analysis
Results are expressed as mean 6 standard error of the mean
(SEM). Group results were compared by one-way analysis of
variance, followed by post hoc Student’s t-test for unpaired
observations or Bonferroni’s correction for multiple comparisons
when appropriate. P,0.05 was considered significant.
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Soluble Wnt Decoy Receptor is Expressed in Lung Cancer
Cell Lines and Binds to Wnt3a
Endogenous Wnt3a and LRP6 levels were assessed in seven
non-small cell lung cancer cell lines (A549, H322, H596, H460,
H358, H2009, and H1299) by western blot analysis. Both Wnt3a
and LRP6 were more strongly expressed in H322, H460, and
H2009 cells than in other cell lines (Fig. 1B and Figure S1);
therefore, H322 and H460 cells were selected to evaluate the
ability of the soluble Wnt decoy receptor (sLRP6E1E2) to inhibit
Wnt signaling. Expression of sLRP6E1E2 from dE1-k35/
sLRP6E1E2-transduced A549 cells was confirmed by western
blot analysis using anti-FLAG antibodies (Fig. 1C). Secretion of
sLRP6E1E2 from dE-k35/sLRP6E1E2-transduced cells was dose-
dependent. To ensure equal loading, transferred proteins were
visualized by staining with Ponceau Red.
To further investigate if sLRP6E1E2 expressed from dE1-k35/
sLRP6E1E2 can interfere the binding ability of endogenous LRP6
to Wnt3a, cell lysates of dE1-k35/LacZ- or dE1-k35/sLRP6E1E2-
transduced H322 and H460 cells which endogenously overexpress
Wnt3a were immunoprecipitated with Wnt3a or LRP6 antibody,
and then endogeneous Wnt3a (top) and total LRP6 (bottom) levels
were detected with anti-Wnt3a and anti-LRP6 antibody. We
observed that both Wnt3a and LRP6 protein levels were lower in
cells transduced with dE1-k35/sLRP6E1E2 than in cells trans-
duced with dE1-k35/LacZ (Fig. 1D), demonstrating that exoge-
nously expressed sLRP6E1E2 can efficiently bind to Wnt3a,
leading to prevention of the interaction between endogenous
LRP6 and Wnt3a.
Decoy Wnt Receptor Decreases Cytosolic b-catenin Level
and TCF Transcriptional Activity
We next hypotheses that secreted sLRP6E1E2 protein inhibit
Wnt signaling by direct binding to Wnt. Therefore, to characterize
the sLRP6E1E2 effects on the Wnt3a/b-catenin signaling, we
determined its effect on b-catenin using a luciferase reporter
system activated by b-catenin/TCF [23]. As shown in Fig. 2A,
luciferase activity was low in A549 cells transduced with dE1-k35/
LacZ or dE1-k35/sLRP6E1E2 in the absence of Wnt3a, since the
endogenous expression level of Wnt3a in A549 is very minimal
(Fig. 1B). Wnt3a treatment increased luciferase expression
approximately 7- to 8-fold in control cells, but not in dE1-k35/
sLRP6E1E2-transduced cells, suggesting that secreted
sLRP6E1E2 could block the signaling effect of exogenously
treated Wnt3a. In the absence of Wnt3a, luciferase activity was
reduced by dE1-k35/sLRP6E1E2 in H460 (48%) and H322 (12%)
cells compared with dE1-k35/LacZ controls (Fig. 2B; P,0.05).
Wnt3a stimulation increased luciferase activity in H460 (53%) and
H322 (102%) cells transduced with dE1-k35/LacZ, but luciferase
activity was significantly lower in dE1-k35/sLRP6E1E2-trans-
duced H460 (48%) and H322 (52%) cells compared with dE1-
k35/LacZ (P,0.05). In order to make this result more compelling,
we investigated the effect of LRP6-specific siRNA (si-LRP6) on the
Wnt3a/b-catenin signaling. As shown in Figure S2, luciferase
activity was significantly reduced by the treatment of si-LRP6 in
both presence and absence of Wnt3a, in agreement with result of
above (Fig. 2).
To evaluate the effect of sLRP6E1E2 on b-catenin localization,
immunofluorescence staining was performed in H322 cells treated
with PBS or transduced with dE1-k35/LacZ or dE1-k35/
sLRP6E1E2. In the absence of Wnt3a, b-catenin staining was
restricted primarily to cell–cell contact sites in all groups. Upon
Wnt3a stimulation, control cells (PBS and dE1-k35/LacZ) showed
reduced b-catenin localization at the plasma membrane, especially
at cell–cell junctions, and increased b-catenin levels in the cytosol
and nucleus. In contrast, dE1-k35/sLRP6E1E2-transduced cells
showed lower levels of cytosolic b-catenin, and higher levels of
membrane-associated b-catenin (Fig. 2C). Quantification of the
nucleus b-catenin expression showed a 98.08% decrease in dE1-
k35/sLRP6E1E2-transduced cells compared with dE1-k35/LacZ
controls in the presence of Wnt3a (Fig. 2D). Results of these
functional studies demonstrate that interactions between
sLRP6E1E2 and Wnt may be sufficient to block Wnt signaling.
Decoy Wnt Receptor sLRP6E1E2 Inhibits Lung Cancer Cell
Proliferation
The Wnt pathway regulates a wide range of cellular functions
including proliferation [24]. To test the effects of sLRP6E1E2 on
proliferation of A549 and H322 cells in vitro, cells were treated with
PBS or transduced with dE1-k35/LacZ or dE1-k35/sLRP6E1E2.
At 72 hr after transduction with dE1-k35/sLRP6E1E2 (20 MOI),
cell proliferation was reduced by 39% in A549 cells and 51% in
H322 cells compared with dE1-k35/LacZ-transduced controls.
Wnt3a stimulation increased proliferation approximately 10–20%
in control cells, but had no apparent effect on dE1-k35/
sLRP6E1E2-transduced cells. Proliferation was 54% lower in
A549 cells and 61% lower in H322 dE1-k35/sLRP6E1E2-
transduced cells than dE1-k35/LacZ-transduced cells (P,0.001;
Fig. 3A).
To characterize signaling pathways involved in the anti-
proliferative action of sLRP6E1E2, we examined its effects on
canonical Wnt signaling. As shown in Fig. 3B, LRP6, Dvl2 and
Axin protein levels in control cells (PBS and dE1-k35/LacZ) were
increased by Wnt3a, but were apparently unaltered by Wnt3a in
dE1-k35/sLRP6E1E2-transduced cells. Similarly, cyclin D1
expression was slightly increased in control cells following Wnt3a
stimulation, but slightly decreased in dE1-k35/sLRP6E1E2-trans-
duced cells. GSK3b levels also appeared slightly decreased after
Wnt3a treatment.
Wnt plays a fundamental role in proliferation by activating
Erk1/2 and PI3K-Akt pathways [25]. We therefore investigated
whether sLRP6E1E2 can downregulate these pathways. As shown
in Fig. 3C, phosphorylation of Erk1/2, PI3K, and Akt was
upregulated by Wnt3a treatment, but levels of phorphorylation
was lower in dE1-k35/sLRP6E1E2-transduced cells compared to
those in PBS-treated and dE1-k35/LacZ-transduced cells. Ex-
pression of mTOR, PI3K, and Akt was not affected by Wnt3a
stimulation, and was lower in dE1-k35/sLRP6E1E2-transduced
cells than controls in H460 cells (Figure S3). Taken together, these
results suggest that sLRP6E1E2 exerts antiproliferative actions by
inhibiting Wnt signaling via MEK-ERK and PI3K- Akt pathways.
Decoy Wnt Receptor sLRP6E1E2 Induces Apoptosis
Wnt signaling can prevent apoptosis and promote cellular
proliferation and survival [26]. To characterize the molecular
mechanisms by which sLRP6E1E2 inhibits non-small cell lung
cancer proliferation, we evaluated the effects of sLRP6E1E2 on
apoptosis. At 3 days after dE1-k35/sLRP6E1E2 transduction, we
observed that A549, H1299, and H358 cells gradually detached
from the culture dish and became rounder and smaller than
attached cells (Fig. 4A), suggesting that sLRP6E1E2 induced
apoptosis. Evidence of apoptosis was sought by looking for nuclear
apoptotic bodies (data not shown), and then assessed using the
TUNEL assay to detect internucleosomal DNA fragmentation
[27]. As shown in Fig. 4B, more TUNEL-positive cells were
observed among dE1-k35/sLRP6E1E2-transduced cells than
among control cells in the presence or absence of Wnt3a.
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36520Figure 2. Decoy Wnt receptor sLRP6E1E2 reduces cytosolic b-catenin and T-cell factor transcriptional activity. (a) TCF/LEF luciferase
reporter assay in A549 cells. To characterize the sLRP6E1E2 effects on the Wnt3a/b-catenin signaling, cells were transfected with TOPflash (containing
wild-type TCF binding sites) or FOPflash (containing mutated TCF binding sites) luciferase vector. *P,0.05 versus dE1-k35/LacZ-transduced or PBS-
treated cells. (b) TCF/LEF luciferase reporter assay in H460 and H322 cells. *P,0.05 versus PBS or dE1-k35/LacZ-transduced cells with or without
Wnt3a. (c) H322 cells were transduced with dE1-k35/LacZ or dE1-k35/sLRP6E1E2 (50 MOI) with or without Wnt3a. Cells were labeled with anti-b-
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36520catenin. Original magnification,6630. (d) Semi-quantitative analysis of panel (c) results using MetaMorphH imaging analysis software. Each data point
indicates mean 6 SEM (each group, n=5). **P,0.001 versus PBS or dE1-k35/LacZ-transduced cells with Wnt3a.
doi:10.1371/journal.pone.0036520.g002
Figure 3. Decoy Wnt receptor sLRP6E1E2 decreases proliferation in human lung cancer cells. (a) A549 and H322 cells were transduced
with dE1-k35/LacZ or dE1-k35/sLRP6E1E2 (20 MOI). The next day, these cells were incubated with or without Wnt3a (100 ng/ml). After 3 days, cell
proliferation was assessed by the MTT assay (mean 6 SEM). *P,0.05,
#P,0.01 versus untreated control for each group; **P,0.001 versus dE1-k35/
LacZ-transduced or PBS-treated cells. n.s. = not significant. (b) A549 cells were treated as indicated above (Fig. 3a). Western blot using antibodies
specific to LRP6, Dvl2, Axin, Cyclin D1, or GSK-3b. (c) A549 cells were harvested at 6 hr after Wnt3a treatment. The p-Erk1/2, Erk1/2, p-PI3K, PI3K, p-Akt,
and Akt proteins were detected by western blot analysis.
doi:10.1371/journal.pone.0036520.g003
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36520Figure 4. Decoy Wnt receptor sLRP6E1E2 induces apoptosis in human lung cancer cells. (a) Cells were transduced with dE1-k35/LacZ or
dE1-k35/sLRP6E1E2 at (20 MOI), and photographs were taken at 72 hr later. Original magnification, 6200. (b) Detection of sLRP6E1E2-induced
apoptosis by TUNEL staining. Original magnification,6400. (c) Total number of TUNEL-positive cells per fields (mean 6 SEM). *P,0.05 versus PBS or
dE1-k35/LacZ treated with Wnt3a; **P,0.001 versus PBS-treated or dE1-k35/LacZ-transduced controls. n.s. = not significant. (d) Western analysis of
sLRP6E1E2-mediated apoptosis. H460 cells were transduced with dE1-k35/LacZ or dE1-k35/sLRP6E1E2 (20 MOI). The western blot using specific
antibodies against uncleaved PARP, cleaved PARP, pro-caspase-3, cleaved caspase-3, and cytochrome c. (e) H460 cells were treated as indicated
above (Fig. 4d). Subcellular localization of cytochrome c was determined by western blot analysis of cytosolic and microsomal fractions.
doi:10.1371/journal.pone.0036520.g004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36520Quantitation of TUNEL staining revealed that the rate of
apoptosis was approximately 1.9-fold higher (without Wnt3a)
and 2.8-fold higher (with Wnt3a) in dE1-k35/sLRP6E1E2-trans-
duced cells than in dE1-k35/LacZ-transduced controls (P,0.001)
(Fig. 4C).
We next evaluated regulators of apoptosis, of which the caspase
family and cytochrome c are the best characterized. In the absence
and presence of Wnt3a, full-length 116-kDa PARP protein was
reduced and 85-kDa cleavage fragments were increased in dE1-
k35/sLRP6E1E2-transduced cells (Fig. 4D). Levels of the cleaved
(active) form of caspase-3 were also markedly increased by
sLRP6E1E2. As shown in Fig. 4E, dE1-k35/sLRP6E1E2-trans-
duced cells also showed increased cytosolic cytochrome c and
decreased microsomal cytochrome c. Stimulation with Wnt3a
produced similar effects.
Decoy Wnt Receptor sLRP6E1E2 Inhibits Tumor
Xenograft Growth
We next evaluated the ability of sLRP6E1E2 to inhibit tumor
growth in a mouse xenograft model. Tumors were generated by
subcutaneous injection of H460 cells into the abdominal region of
nude mice. When tumors reached a mean size of 80–100 mm
3,
they were injected with PBS, dE1-k35, RdB-k35, dE1-k35/
sLRP6E1E2, or RdB-k35/sLRP6E1E2 on days 1, 3, and 5.
Fig. 5A shows that the volume of tumors injected with
sLRP6E1E2-expressing vectors was significantly lower than that
of corresponding controls. After 25 days, tumors treated with PBS
reached a mean volume of 3883.16418.08 mm
3, and tumors
treated with dE1-k35 and RdB-k35 reached 3388.16226.9 mm
3
and 19916311.8 mm
3, respectively. In contrast, tumor growth
was strongly suppressed in mice injected with dE1-k35/
sLRP6E1E2 (1645.36353.6 mm
3; P,0.05 compared with PBS
or dE1-k35 groups) or RdB-k35/sLRP6E1E2 (923.36180.4 mm
3;
P,0.01 compared with PBS or RdB-k35 groups).
To evaluate the biological effects of sLRP6E1E2 in tumor tissue,
tumors were harvested 3 days after the final adenovirus injection.
Analysis of adenoviral E1A protein expression revealed that RdB-
k35 and RdB-k35/sLRP6E1E2 had replicated and spread through
the tumor (Fig. 5B, E1A). Immunohistochemical analysis of
sLRP6E1E2 (Fig. 5B, FLAG) showed that its expression was more
widespread in RdB-k35/sLRP6E1E2-treated tumors than in dE1-
k35/sLRP6E1E2-treated tumors, indicating that the oncolytic
adenovirus more efficiently expressed sLRP6E1E2 than the
replication-incompetent adenovirus, contributing to its superior
antitumor actions.
Anti-proliferative and Apoptotic Effects of sLRP6E1E2-
expressing Vectors in H460 Xenografts
To assess the effects of sLRP6E1E2 on tumor xenograft growth
in mice, tumor samples were analyzed by Ki-67 immunostaining
for proliferating cells and TUNEL staining for apoptotic cells. We
found that Ki-67 expression was reduced and TUNEL-positive
cells were increased in tumors treated with dE1-k35/sLRP6E1E2
or RdB-k35/sLRP6E1E2 compared with corresponding controls
(Fig. 5C). We also detected more TUNEL-positive cells in RdB-
k35/sLRP6E1E2-treated tumors than in dE1-k35/sLRP6E1E2-
treated tumors, consistent with previous results. To determine
whether the smaller sLRP6E1E2-treated tumors exhibited re-
duced neovascularization, microvessel density was assessed by
CD31 staining. Fewer endothelial cells and vessel structures was
observed in tissues injected with E1-expressing oncolytic adeno-
viruses (RdB-k35 and RdB-k35/sLRP6E1E2) than PBS-treated
tumors (P,0.05), whereas no significant decrease in vascular
density was observed in tumors injected with dE1-k35 or dE1-
k35/sLRP6E1E2 (Fig. 5D & 5E). Further, vessel density in tumors
injected with sLRP6E1E2-expressing adenoviruses did not differ
from their corresponding controls, suggesting that the antitumor
properties of sLRP6E1E2 were not mediated by anti-angiogenic
effects.
To further investigate the role of Wnt signaling in the antitumor
actions of sLRP6E1E2-expressing adenoviruses, Wnt and b-
catenin localization in tumor tissue was evaluated. High endog-
enous expression of b-catenin and Wnt was observed in tumor
tissues treated with PBS or control vectors (dE1-k35 and RdB-k35)
(Fig. 5F-H), but was significantly reduced by sLRP6E1E2-
expressing vectors, suggesting that blockade of Wnt signaling in
tumor cells was an important contributor to slower tumor growth.
Wnt Treatment Results Altered Cell Morphology and
Induces EMT in Tumor Cells
EMT is an important process in tumor development, and the
Wnt/b-catenin signal pathway may play an important role in this
process. Therefore, we investigated whether Wnt3a could induce
EMT in H322 cells. We found that cells became elongated and
spindle-shaped 1 day after Wnt3a treatment, resembling the
morphology of mesenchymal cells (Fig. 6A). We also observed
increased expression of mesenchymal markers Vimentin and b-
catenin with a concomitant decrease in epithelial marker E-
cadherin (Fig. 6B). Immunofluorescence staining revealed that
actin and E-cadherin levels were dramatically reduced in cell–cell
contacts after Wnt3a treatment (Fig. 6C and Figure S5).
sLRP6E1E2 Modulates EMT-related Marker Expression
and MMP-2/MMP-9 Activity
Acquisition of migratory properties by cancer cells is important
for metastatic tumor cell spread [28]. Because increasing Wnt3a
appeared to enhance motility and invasiveness, we asked whether
interfering with the Wnt signaling pathway by expressing
sLRP6E1E2 would inhibit in vitro motility and invasion. We
examined the effect of sLRP6E1E2 on A549 cells using transwell
motility and matrigel invasion assays. We collected conditioned
medium from PBS-treated, dE1-k35/LacZ-transduced, and dE1-
k35/sLRP6E1E2-transduced cells after treatment with or without
Wnt3a. Conditioned medium from dE1-k35/sLRP6E1E2-trans-
duced cells inhibited migration by 12.4% (without Wnt3a) and
23.8% (with Wnt3a) compared with conditioned medium from
dE1-k35/LacZ-transduced cells (P,0.001) (Fig. 7A). Similarly,
conditioned medium from dE1-k35/sLRP6E1E2-transduced cells
inhibited invasion by 34.2% (without Wnt3a) and 56.2% (with
Wnt3a) compared with conditioned medium from dE1-k35/LacZ-
transduced cells (Fig. 7B).
EMT has been shown to be important for cancer progression
and metastasis. Therefore, we examined whether sLRP6E1E2 can
modulate EMT-related markers associated with tumor invasion in
H322 cell. Figure 7C and Figure S5 showed that dE1-k35/
sLRP6E1E2-transduced cells exhibited up-regulation of epithelial
markers E-cadherin and actin by immunofluorescent staining.
Conversely, mesenchymal markers (i.e., N-cadherin and vimentin)
were markedly down-regulated in dE1-k35/sLRP6E1E2-trans-
duced cells (Fig. 7D, upper panel). The expression of transcription
factor Snail which is known to repress E-cadherin and promote
a mesenchymal phenotype [29] was also down-regulated (Fig. 7D,
lower panel). Together, these data further support the role of
sLRP6E1E2 in modulating EMT-related events.
Several MMPs are additional Wnt target genes that play an
important role in promoting invasion and metastasis of malig-
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36520Figure 5. Decoy Wnt receptor sLRP6E1E2 inhibits tumor growth and characterization. (a) Tumors were injected with PBS (&), dE1-k35/
LacZ (¤), RdB-k35 (m), dE1-k35/sLRP6E1E2 (6), or RdB-k35/sLRP6E1E2 (N) on days 1, 3, and 5. Results are expressed as mean 6 SEM (n=7). *P,0.05
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of sLRP6E1E2 on expression of MMP-2 and MMP-9, which play
a critical role in angiogenesis, tumor growth, and metastasis. As
shown in Fig. 7E and F, Wnt3a stimulation upregulated MMP-2
and MMP-9 enzyme activity in PBS-treated and dE1-k35/LacZ-
transduced A549 cells, but dE1-k35/sLRP6E1E2-transduced cells
showed low MMP-2 and MMP-9 enzyme activity with or without
Wnt3a treatment. Taken together, these findings suggest that
sLRP6E1E2 affected multiple Wnt-related pathways in human
non-small cell lung cancer cell lines, leading to reduced cellular
invasiveness.
Discussion
Aberrant activation of the Wnt pathway contributes to human
cancer progression [32]. Accordingly, monoclonal antibodies
against Wnt ligands [33,34] and overexpression of Wnt antago-
nists [35,36] are able to reduce in vivo tumor growth. Members of
the sFRP family bind directly to Wnts, inhibiting their ability to
bind to the Wnt receptor complex. The Fzd8 soluble extracellular
domain suppresses Wnt-driven tumor growth in vivo [10] and two
sFRPs, FrzA and FrzB inhibited Wnt-1–mediated increase in
cytoplasmic b-catenin levels, TCF transcriptional activity in vitro,
and tumor growth and metastasis [37].
Antagonists that interfere with Wnt ligand/receptor interactions
may therefore be potent cancer treatments. However, primary
human tumors and cancer cell lines express multiple Wnt and Fzd
receptors, and the specificity of Wnt proteins for the various
receptors is unclear [37]. Therefore, it is difficult to design a Wnt
antagonist that can block these interactions. Recently, Lu et al.
reported that cotransfection of vectors expressing Wnt3 and LRP6
receptor increased TCF activation [38], suggesting the therapeutic
potential of a soluble LRP6 receptor as a Wnt antagonist.
versus PBS-treated or dE1-k35-treated controls and versus dE1-k35/sLRP6E1E2.
#P,0.01 versus PBS-treated or dE1-k35-treated controls. (b) Tumor
sections from each group were immunostained against E1A or FLAG (original magnification,640 and6100). (c) Tumor tissues from each group were
stained with DAPI (blue), anti-Ki67 (red), and TdT-mediated TUNEL (green). Original magnification:6100. (d) Blood vessels were visualized by staining
for CD31. Original magnification, 6100. (e) Mean microvessel density for each treatment group (CD31 positive cells/field). Results are expressed as
mean 6 SEM (each group, n=3 tumors). *P,0.05 versus PBS, dE1-k35, or dE1-k35/sLRP6E1E2. n.s. = not significant. (f) Cells were stained with DAPI
(blue), anti-Wnt3a (red), or anti-b-catenin (green). Original magnification: 6100. (g, h) The expression levels of Wnt3a (g) and b-catenin (h) were
assessed semi-quantitatively using MetaMorphH imaging analysis software. Results are expressed as mean 6 SEM (each group, n=5 tumors).
#P,0.01 versus dE1-k35, *P,0.05 versus RdB-k35.
doi:10.1371/journal.pone.0036520.g005
Figure 6. Wnt3a treatment results in the disruption of cell-cell junctions and epithelial-to-mesenchymal transition in tumor cells. (a)
H322 cells were treated with Wnt3a (100 ng/ml) for the indicated times, and morphology changes were observed by light microscopy. Original
magnification,6200. (b) E-cadherin, Vimentin, and b-catenin mRNA levels in H322 cells after Wnt3a treatment. (c) H322 cells were stained with DAPI
(blue), TRITC-labeled actin (red), or anti E-cadherin (green) after 24 incubation with or without Wnt3a (100 ng/ml). Original magnification, 6630.
doi:10.1371/journal.pone.0036520.g006
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mesenchymal transition markers and MMPs. (a) Quantitative analysis of A549 lung cancer cell migration. Experiments were performed in
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repeats required for functional interaction with Wnt.
In the present study, we demonstrated that sLRP6E1E2 is
secreted and binds specifically to Wnt3a, as evidenced by
decreased endogenous Wnt3a and LRP6 levels after transduction
with sLRP6E1E2-expressing adenoviruses (Fig. 1). Wnt signaling
affects multiple targets; therefore, we then assessed the effect of
sLRP6E1E2 on pathways responsible for tumor growth, invasion,
and metastasis. Our in vitro studies showed that sLRP6E1E2
reduced cell proliferation by inhibiting MEK-ERK and PI3K- Akt
signaling (Fig. 3A, C and Figure S3). Since PI3K-Akt signaling
regulates cell survival and apoptosis [39], the ability of
sLRP6E1E2 to induce apoptosis was assessed. As shown in
Fig. 4, dE1-k35/sLRP6E1E2 transduction increased cytosolic
cytochrome c levels, consistent with apoptosis through a mitochon-
dria-dependent pathway.
Limitations of replication-incompetent adenoviruses for cancer
therapy include nonselective delivery of therapeutic genes to both
normal and tumor cells, and inability to replicate and spread to
neighboring tumor cells. To improve the therapeutic value of
adenovirus-mediated gene therapy, a cancer cell-specific replicat-
ing adenovirus (oncolytic adenovirus) has been developed [40].
Our group previously developed RdB, an E1A-E1B double
mutant oncolytic adenovirus with higher cancer cell-specific
cytotoxicity and viral replication than E1A or E1B single mutant
oncolytic adenoviruses [19]. As shown in Fig. 5, tumors treated
with RdB-k35/sLRP6E1E2 were 54% smaller than tumors treated
with the oncolytic adenovirus not expressing sLRP6E1E2 (RdB-
k35) and 44% smaller than those treated with the non-replicating
dE1-k35/sLRP6E1E2. RdB-k35/sLRP6E1E2 increased apopto-
sis, but also exerted anti-angiogenic effects. Immunostaining tumor
tissues against CD31, a marker of angiogenesis, showed that the
control oncolytic adenovirus RdB-k35 produced effects similar to
that of RdB-k35/sLRP6E1E2. We and other groups previously
demonstrated that replication-competent adenoviruses suppress
tumor angiogenesis through the preserved E1A region [17,41,42],
indicating that sLRP6E1E2 expression from the vectors does not
play a role in reducing tumor angiogenesis.
During tumor metastasis, disseminated cancer cells appear to
require the ability to self-renew, similar to that exhibited by stem
cells. Our results show that Wnt signaling upregulates EMT-
related molecules Vimentin and b-catenin and increased tumor
cell migration and invasion (Fig. 6 and Figure S4). Cells were more
compact and adhesive after treatment with the sLRP6E1E2-
expressing adenovirus (data not shown), with increased expression
of epithelial markers (E-cadherin and actin filaments) and down-
regulation of mesenchymal markers (vimentin, N-cadherin, and
Snail) (Fig. 7C and D). Moreover, sLRP6E1E2 reduced expression
of MMP-2/MMP-9, which correlate with tumorigenicity and
metastatic potential of cancer cells [43]. Therefore, it is important
to determine whether targeting Wnt ligand-receptor interactions
will reduce tumor recurrence and/or metastasis, warranting future
investigation.
Many studies have demonstrated the association between
aberrant expression of Wnt ligands/receptors and human cancer
development/progression. The current study demonstrates for the
first time that a decoy receptor consisting of LRP6 Wnt-binding
domains can effectively inhibit Wnt signaling and downregulate
potential Wnt targets. In addition, sLRP6E1E2 markedly reduced
tumor growth, invasion, and EMT. Taken together, our findings
demonstrate the therapeutic potential of sLRP6E1E2 as a novel
cancer gene therapy. Ongoing studies in our laboratories are
aimed at determining the efficacy of sLRP6E1E2 against cancer
stem cells.
Supporting Information
Figure S1 Endogenous LRP6 and Wnt3a expression in HT1299
human lung cancer cells. Western blot using antibodies specific to
Wnt3a or LRP6.
(TIF)
Figure S2 The effect of LPR6 knockdown on b-catenin/TCF
transcriptional activity. H460 (a) and H322 (b) cells were co-
transfected with TOPflash vector and LRP6 siRNA or control
siRNA (si-Scramble) in the presence or absence of Wnt3a for
16 hr as described in Materials and Methods. **P,0.001 versus si-
Scramble-transfected cells with or without Wnt3a.
(TIF)
Figure S3 Decoy Wnt receptor sLRP6E1E2 decreases pro-
liferation signaling of human lung cancer cells. H460 cells were
transduced with dE1-k35/LacZ or dE1-k35/sLRP6E1E2
(50 MOI) as described in Materials and Methods. The expression
levels of MEK, Erk1/2, Survivin, mTOR, PI3K, and Akt was
assessed by Western blot analysis.
(TIF)
Figure S4 sLRP6E1E2 decreases motility of H322 and H460
cancer cells. Cell migration was studied using a modified transwell
migration chamber. (a) H322 and (b) H460 cells were transduced
with dE1-k35/LacZ or dE1-k35/sLRP6E1E2 in the presence or
absence of Wnt3a for 16 hr as described in Materials and
Methods. Cells were then allowed to migrate for 20–24 hr.
Migration was evaluated relative to untreated cells (100%). Assays
were performed in triplicate and data shown are one represen-
tative experiment of three independent experiments performed.
Results are reported as the mean 6 SEM of 10 independent high
power fields/well.
#P,0.01, **P,0.001 versus PBS- or dE1-k35/
LacZ-treated controls.
(TIF)
Figure S5 Decoy Wnt receptor sLRP6E1E2 inhibits epithelial-
to-mesenchymal transition. Expression of EMT markers in H322
cells after 24 hr treatment with PBS, dE1-k35/LacZ, or dE1-k35/
sLRP6E1E2 in the presence or absence of Wnt3a (100 ng/ml).
Cells were stained with DAPI (blue), TRITC-labeled actin (red), or
anti E-cadherin (green). Original magnification, 6400.
(TIF)
triplicate, and results are expressed as mean 6 SEM. *P,0.05 versus PBS- or dE1-k35/LacZ-treated controls; **P,0.001 versus PBS or dE1-k35/LacZ
with Wnt3a. (b) Invasion of tumor cells was quantified as number of cells in five fields of view per filter. Experiments were performed in triplicate, and
results are expressed as mean 6 SEM. *P,0.05 versus PBS- or dE1-k35/LacZ-treated controls; **P,0.001 versus PBS or dE1-k35/LacZ with Wnt3a. (c)
Expression of EMT markers in H322 cells after 24 hr treatment with PBS, dE1-k35/LacZ, or dE1-k35/sLRP6E1E2 in the presence and absence of Wnt3a
(100 ng/ml). Cells were stained with DAPI (blue), TRITC-labeled actin (red), or anti E-cadherin (green). Original magnification,6630. (d) Expression of
EMT-related markers in H322 cell lines. Expression levels of mesenchymal markers (N-cadherin & vimentin) as well as transcriptional factor (Snail) was
determined by Western blotting. (e, f) A549 cells were transduced with dE1-k35/LacZ or dE1-k35/sLRP6E1E2 with or without Wnt3a (100 ng/ml). The
enzyme activity of MMP-2 and MMP-9 was measured in supernatants collected from transduced cells at 48 hr using the Sensolyte 520 MMP-2 and
MMP-9 assay kit. Experiments were performed in triplicate, and results are expressed as mean 6 SEM. (e) *P,0.05, (f)
#P,0.01 versus PBS- or dE1-
k35/LacZ-treated controls; (e)
#P,0.01, (f) **P,0.001 versus PBS or dE1-k35/LacZ with Wnt3a.
doi:10.1371/journal.pone.0036520.g007
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